Vikas Sinha
Präsident bei ALLOVIR, INC.
Vermögen: 2 Mio $ am 30.04.2024
Profil
Vikas Sinha is the founder of ElevateBio LLC, a company founded in 2017, where he holds the title of Chief Financial Officer & Director.
He is currently working as an Independent Non-Executive Director at Verona Pharma Plc since 2016, President, Chief Financial Officer & Director at AlloVir, Inc. since 2019, Director at LifeEDIT Therapeutics, Inc., and Associate Member at The Institute of Chartered Accountants of India.
Previously, he worked as an Independent Director at BCLS Acquisition Corp.
from 2020 to 2022, Chief Financial Officer & Executive Vice President at Alexion Pharmaceuticals, Inc. from 2012 to 2016, Manager-Mergers & Acquisitions at Bayer AG from 1994 to 2005, Chief Financial Officer & Vice President at Bayer Pharmaceuticals Corp.
from 2001 to 2005, Chief Financial Officer & Vice President at Bayer Yakuhin Ltd., and Principal at ANZ Banking Corp.
He obtained an MBA from Asian Institute of Management in 1994 and completed his undergraduate degree from Tribhuvan University.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
VERONA PHARMA PLC
0,12% | 29.04.2024 | 595 520 ( 0,12% ) | 1 Mio $ | 30.04.2024 |
ALLOVIR INC
0,98% | 17.05.2024 | 1 129 996 ( 0,98% ) | 903 997 $ | 30.04.2024 |
Aktive Positionen von Vikas Sinha
| Unternehmen | Position | Beginn |
|---|---|---|
| VERONA PHARMA PLC | Direktor/Vorstandsmitglied | 12.09.2016 |
| ALLOVIR, INC. | Präsident | 01.09.2018 |
ElevateBio LLC
 ElevateBio LLC BiotechnologyHealth Technology ElevateBio LLC is a biotechnology holding company, which creates and operates a broad portfolio of cell and gene therapy companies. It builds single and multi-product companies by providing scientific founders with bench-to-bedside capabilities including scientists, manufacturing facilities, drug developers, and commercial expertise. The company was founded by David L. Hallal, Vikas Sinha, and Mitchell H. Finer and is headquartered in Cambridge, MA. | Gründer | 01.12.2017 |
| The Institute of Chartered Accountants of India | Corporate Officer/Principal | - |
LifeEDIT Therapeutics, Inc.
 LifeEDIT Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Part of ElevateBio LLC, LifeEDIT Therapeutics, Inc. is a next-generation genome editing company that has built a highly innovative platform with one of the world's largest and most diverse collections of novel RNA-guided nucleases (RGNs) and base editors. The company offers gene editing tools with higher fidelity, novel functionality, reduced immune response risk, and easier delivery. LifeEDIT has a large and diverse library of RGNs, including type II and type V systems that encompass knock-out and knock-in capabilities, transcriptional regulation, and base editing when coupled with one of their proprietary deaminases. The company's nuclease collection has a broad range of protospacer adjacent motifs (PAMs), offering unprecedented access to genomes. LifeEDIT is headquartered in Morrisville, NC. The CEO of the company is Mitchell H. Finer. LifeEDIT Therapeutics was acquired by ElevateBio LLC from AgBiome Delta LLC on October 27, 2021. | Direktor/Vorstandsmitglied | - |
Ehemalige bekannte Positionen von Vikas Sinha
| Unternehmen | Position | Ende |
|---|---|---|
| BCLS ACQUISITION CORP. | Direktor/Vorstandsmitglied | 01.12.2022 |
| ALEXION PHARMACEUTICALS, INC. | Finanzdirektor/CFO | 12.12.2016 |
| Bayer Pharmaceuticals Corp. | Finanzdirektor/CFO | - |
| BAYER AG | Corporate Officer/Principal | - |
| ░░░ ░░░░░░░ ░░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | - |
Ausbildung von Vikas Sinha
| Asian Institute of Management | Masters Business Admin |
| Tribhuvan University | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 3 |
|---|---|
| BAYER AG | Health Technology |
| VERONA PHARMA PLC | Health Technology |
| ALLOVIR, INC. | Health Technology |
| Private Unternehmen | 7 |
|---|---|
Alexion Pharmaceuticals, Inc.
 Alexion Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Alexion Pharmaceuticals, Inc. engages in the business of serving patients and families affected by rare diseases and devastating conditions through the discovery, development, and commercialization of life-changing medicines. The firm also focuses on the development of haematology, nephrology, neurology, metabolic disorders, cardiology, and ophthalmology. The company was founded by Joseph A. Madri, David W. Keiser, Stephen P. Squinto, and Leonard Bell in January 1992 and is headquartered in Boston, MA. | Health Technology |
| Bayer Pharmaceuticals Corp. | |
Bayer Yakuhin Ltd.
 Bayer Yakuhin Ltd. Pharmaceuticals: MajorHealth Technology Part of Bayer AG, Bayer Yakuhin Ltd. is a Japanese company that manufactures pharmaceuticals and diagnostic substances. The company is based in Osaka, Japan. | Health Technology |
ANZ Banking Corp.
 ANZ Banking Corp. Regional BanksFinance ANZ Banking Corp. provides commercial banking services. The company is headquartered in Northcote, Australia. | Finance |
ElevateBio LLC
ElevateBio LLC BiotechnologyHealth Technology ElevateBio LLC is a biotechnology holding company, which creates and operates a broad portfolio of cell and gene therapy companies. It builds single and multi-product companies by providing scientific founders with bench-to-bedside capabilities including scientists, manufacturing facilities, drug developers, and commercial expertise. The company was founded by David L. Hallal, Vikas Sinha, and Mitchell H. Finer and is headquartered in Cambridge, MA. | Health Technology |
BCLS Acquisition Corp.
 BCLS Acquisition Corp. Financial ConglomeratesFinance BCLS Acquisition Corp. is a blank check company, which engages in seeking a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses. The company was founded on August 26, 2020 and is headquartered in Boston, MA. | Finance |
LifeEDIT Therapeutics, Inc.
LifeEDIT Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Part of ElevateBio LLC, LifeEDIT Therapeutics, Inc. is a next-generation genome editing company that has built a highly innovative platform with one of the world's largest and most diverse collections of novel RNA-guided nucleases (RGNs) and base editors. The company offers gene editing tools with higher fidelity, novel functionality, reduced immune response risk, and easier delivery. LifeEDIT has a large and diverse library of RGNs, including type II and type V systems that encompass knock-out and knock-in capabilities, transcriptional regulation, and base editing when coupled with one of their proprietary deaminases. The company's nuclease collection has a broad range of protospacer adjacent motifs (PAMs), offering unprecedented access to genomes. LifeEDIT is headquartered in Morrisville, NC. The CEO of the company is Mitchell H. Finer. LifeEDIT Therapeutics was acquired by ElevateBio LLC from AgBiome Delta LLC on October 27, 2021. | Commercial Services |
